Captor Therapeutics ® Investor Relations

      Investor Relations

      Appointment of the Company's Supervisory Board, Management Board, Audit Committee and Remuneration Committee for the next term

      Publication date: 2022-06-30
      Number: RB ESPI 27/2022

      Current Report No. 27/2022

      Date of preparation: 30 June 2022

      Subject: Appointment of the Company's Supervisory Board, Management Board, Audit Committee and Remuneration Committee for the next term

      Legal basis: Article 56(1)(2) of the Act on Public Offering - current and periodic information

      The Management Board of Captor Therapeutics S.A. ("Company"), informs that on 30 June 2022 Ordinary General Meeting elected the following persons as members of the Company's Supervisory Board for the next common term of 3 (three) years:

      1. Mr Paul Holstinghausen Holsten;
      2. Mr Robert Florczykowski;
      3. Mr Florent Gros;
      4. Mr Krzysztof Samotij;
      5. Mr Maciej Wróblewski.

      The criteria for independence from the Company and entities with significant connections with the Company set out in Article 129(3) of the Act of 11 May 2017 on auditors, audit firms and public supervision (i.e. Journal of Laws of 2022, item 1302) (the "Act") are met by the following members of the Supervisory Board:

      1. Mr Robert Florczykowski;
      2. Mr Florent Gros;
      3. Mr Krzysztof Samotij.

      The Company announces that the CVs of all Supervisory Board members can be found on the Company's website under the tab: "Investor Relations", under the heading: "Company", sub-heading: "Supervisory Board" (link: https://www.captortherapeutics.pl/relacje-inwestorskie/spolka/rada-nadzorcza).

      The Supervisory Board of the Company on 30 June 2022 , on the basis of § 28 (1) of the Company's Articles of Association, decided to appoint Mr Paul Holstinghausen Holsten as Chairman of the Supervisory Board of the Company for a further joint term of 3 (three) years.

      At the same time, the Company announces that the Company's Supervisory Board, in connection with the expiry of the mandates of the existing members of the Management Board, pursuant to § 16.2 of the Company's Articles of Association, decided on 30 June 2022 to appoint the following persons to the Company's Management Board for another joint 3 (three) year term of office:

      1. Mr Thomas Shepherd as Chairman of the Company's Board of Directors;
      2. Mr Radosław Krawczyk for the position of Member of the Management Board - Financial Director of the Company;
      3. Mr Michał Walczak for the position of Member of the Management Board - Scientific Director of the Company. 

      The Company announces that the CVs of all Board members can be found on the Company's website under the tab: "Investor Relations", under the heading: "Company", sub-heading: "Management Board" (link: https://www.captortherapeutics.pl/relacje-inwestorskie/spolka/zarzad).

      At the same time, no member of the Company's Management Board or Supervisory Board conducts any activity competitive to the activity pursued by the Company and, at the same time, does not participate in a competitive company as a partner in a civil partnership, a partnership or as a member of the authority of a joint stock company, or in another competitive legal person as a member of its authority. The above persons were also not entered in the Register of Insolvent Debtors kept pursuant to the Act of 20 August 1997 on the National Court Register (i.e. Journal of Laws of 2021, item 112, as amended).

      At the same time, the Company's Supervisory Board decided to appoint, pursuant to § 29, section 1 of the Company's Articles of Association in connection with Article 128, section 1 of the Act, the following members of the Company's Supervisory Board as members of the Audit Committee for the next joint 3 (three) year term of office:

      1. Krzysztof Samotij as Chairman of the Audit Committee;
      2. Maciej Wróblewski as a member of the Audit Committee;
      3. Florent Gros as a member of the Audit Committee.

      In addition, the Company's Supervisory Board, pursuant to § 29.3 of the Company's Articles of Association, also appointed the Company's Remuneration Committee for a further joint 3 (three) year term of office. It was composed of the following persons from among the members of the Company's Supervisory Board:

      1. Mr Paul Holstinghausen Holsten acting as a member of the Remuneration Committee;
      2. Mr Robert Florczykowski acting as a member of the Remuneration Committee;
      3. Mr Florent Gros acting as a member of the Remuneration Committee.

       

      Detailed legal basis:

      art. 56 sec. 1 item. 2 of the Act on Public Offering and Conditions Governing the Introduction of Financial Instruments to Organised Trading and on Public Companies in connection with § 5 (5) of the Regulation of the Minister of Finance of 29 March 2018 on current and periodic information provided by issuers of securities and conditions for recognising as equivalent information required by the laws of a non-member state.